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In light of the number of studies conducted to examine the
treatment of cognitive impairment associated with schizo-
phrenia (CIAS), we critically reviewed recent CIAS trials.
Trials were identified through searches of the website
‘‘www.clinicaltrials.gov’’ using the terms ‘‘schizophrenia
AND cognition,’’ ‘‘schizophrenia AND neurocognition,’’
‘‘schizophrenia AND neurocognitive tests,’’ ‘‘schizophrenia
ANDMATRICS,’’ ‘‘schizophrenia ANDMCCB,’’ ‘‘schizo-
phreniaANDBACS,’’ ‘‘schizophreniaANDCOGSTATE,’’
and ‘‘schizophrenia AND CANTAB’’ and ‘‘first-episode
schizophrenia AND cognition.’’ The cutoff date was 20 April
2011. Included trials were conducted in people with schizo-
phrenia, the effects on cognition were either a primary or sec-
ondary outcome, and the effect of a pharmacologically active
substance was examined. Drug challenge, pharmacokinetic,
pharmacodynamic, or prodrome of psychosis studies were ex-
cluded. We identified 118 trials, with 62% using an add-on
parallel group design. The large majority of completed trials
were underpowered to detect moderate effect sizes, had £8
weeks duration, and were performed in samples of partici-
pants with chronic stable schizophrenia. The ongoing add-
on trials are longer, have larger sample sizes (with a number
of them being adequately powered to detect moderate effect
sizes), and are more likely to use a widely accepted standard-
ized cognitive battery (eg, the MATRICS Consensus Cogni-
tive Battery) and MATRICS guidelines. Ongoing studies
performed in subjects with recent onset schizophrenia may
help elucidate which subjects are most likely to show an effect
in cognition. New insights into the demands of CIAS trial
design and methodology may help increase the probability





Neurocognitive impairments are a core component of
schizophrenia. They include significant deficits in
memory, attention, working memory, problem solving,
processing speed, and social cognition.1–3 These impair-
ments have been shown to be associated with various im-
paired functional outcomes.4,5 The severity of cognitive
impairment predicts poorer treatment adherence6,7 and
increased relapse risk in first-episode patients.8 Further-
more, imaging studies have demonstrated relationships
between cognitive deficits and structural or functional
brain abnormalities.9–13 Due to the clinical relevance
of neurocognitive impairment in schizophrenia and in
particular its relationship to poor functional outcomes,
development of new therapies to enhance cognition
in schizophrenia remains one of the most pressing
challenges in psychopharmacology.1,14–16
The joint academic, government, and industry Mea-
surement and Treatment Research to Improve Cognition
in Schizophrenia (MATRICS) initiative facilitated the
development of guidelines for the design of clinical trials
of drugs for neurocognitive impairment in schizophre-
nia17 and created the MATRICS Consensus Cognitive
Battery (MCCB)18,19 for measuring cognitive treatment
outcomes in schizophrenia. Based on experience from
early studies that used the MATRICS clinical trial guide-
lines, the MATRICS investigators recommended revi-
sion of the inclusion criteria to enhance recruitment
while maintaining sufficient methodological rigor.20
The proposed revisions relaxed the symptom inclusion
criteria for hallucinations and delusions, removed the
negative symptom criterion, and revised the antipsy-
chotic medication inclusion criterion to include first gen-
eration antipsychotics in the context of no concomitant
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anticholinergic agents and minimal extrapyramidal
symptoms. Antipsychotic polypharmacy is now allowed
in the absence of pertinent pharmacodynamic/pharmaco-
kinetic considerations.
In view of the activities related to the treatment of cog-
nitive impairment associated with schizophrenia (CIAS),
and in particular, the number of clinical trials involving
pharmacological treatments of CIAS, we critically
reviewed recent CIAS trials to answer the following ques-
tions: (a) What has been learned so far? (b) Which factors
may contribute to negative study results? (c) What are we
likely to learn from ongoing studies? and (d) How may
these lessons help shape future trials?
Methods
To identify trials for inclusion in the analysis, we per-
formed a search of the website ‘‘www.clinicaltrials.gov.’’
Trial registration on this trial registry started in 2000 for
National Institute of Health grants and in 2002 for indus-
try-sponsored trials. We used the following search terms
‘‘schizophrenia AND cognition,’’ ‘‘schizophrenia AND
neurocognition,’’ ‘‘schizophrenia AND neurocognitive
tests,’’ ‘‘schizophrenia AND MATRICS,’’ ‘‘schizophre-
nia AND MCCB,’’ ‘‘schizophrenia AND BACS,’’
‘‘schizophrenia AND COGSTATE,’’ and ‘‘schizophre-
nia AND CANTAB’’ and ‘‘first-episode schizophrenia
AND cognition.’’ The cutoff date for these searches
was April 20, 2011. Trials identified through this initial
search were individually screened, and ones fulfilling
the following criteria were included in the analysis
 Conducted in people with schizophrenia
 The effects on cognition were either a primary or sec-
ondary outcome
 The effect of a pharmacologically active substance was
examined (as a monotherapy, add-on therapy, or in
combination with other nonpharmacological therapeu-
tic method, eg, cognitive remediation)
 Not a drug challenge, pharmacokinetic, pharmacody-
namic, or prodrome of psychosis study
Identified trials were grouped into completed ongoing
and terminated trials and then subsequently classified by
the following study designs: (1) trials using add-on, pla-
cebo-controlled parallel group design and (2) trials using
other designs (crossover open-label monotherapy paral-
lel-group and monotherapy single group, post switch
open-label design).
For each trial included in the analysis, the following
information was manually retrieved from the trial de-
scription at www.clinicaltrials.gov and tabulated
 Pharmacological agent under study
 Putative mechanism of action
 Trial NCT registration number
 Sponsor
 Start date
 Current status of the trial
 Indication
 Dose
 Participant population characteristics as per inclusion
and exclusion criteria
 Baseline cognitive impairment as an inclusion criterion
and its definition (where applicable)
 Study design
 Biomarkers examined in the study (if applicable)
 Other outcome variables
For each completed trial, information on results was
retrieved from www.clinicaltrials.gov, and supplemental
searches were performed on PubMed, Google, and Goo-
gle Scholar to identify additional results available in the
public domain (eg, publications, published abstracts, or
press releases). For the completed trials with available
results, a summary of those results along with age-related
variables (mean age, years since diagnosis and age at on-
set of illness) and baseline cognitive test scores were pre-
sented. For terminated trials, a brief description of the
reason(s) for termination was also extracted based on
available information. The results were displayed in tab-
ular format and summarized using descriptive statistics
where appropriate. For double-blind add-on trials, we
also included information on whether the study had suf-
ficient statistical power (beta = .80) to identify true treat-
ment differences based upon the following assumptions:
2-tailed alpha of .05, test-retest of the primary outcome
of intraclass correlation (ICC) = .90 (consistent with the
MCCB composite score in multisite studies)21 and true
effect sizes of d = 0.5 (medium effect) and d = 0.8 (large
effect), which resulted in observed effect sizes of 0.47
and 0.76, respectively. Note that these assumptions were
notstrictlymet insomecases, especially for studiesusingout-
comemeasures with lower reliability and study designs with
multiple treatment arms. We present in figure 1, the sample
size requirements to achieve power of beta = .80 for various
effect size estimates and test-retest reliabilities.
Results
Our analysis included 118 studies that satisfied inclusion
criteria.
Terminated Trials
We identified 11 terminated trials (6 add-on, placebo-
controlled double-blind trials; 1 cross-sectional prospec-
tive add-on trial; 1 open-label trial; and 3 monotherapy
trials) (see online supplementary table 1). TheMCCB18,19
was the primary outcome measure in 3 trials; the neuro-
psychological assessments varied across the remainder of
the terminated trials. Two trials were terminated due to
difficulties with recruitment, 1 trial at the sponsor’s
. S. E. K efe et al.
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request due to adverse animal toxicology data, 4 trials
due to a lack of any apparent clinical benefit, and the
sponsor of 1 trial closed their neuroscience program.
The results of the last trial are being analyzed by an ac-
ademic consortium (Keefe, personal communication).
For the remaining trials, the sponsor terminated the
study prior to recruitment start without providing any
reasons for the decision, in 1 trial, the compound was
withdrawn from the market in European Union, and
for 1 trial, no information was provided. We will not dis-
cuss terminated studies in any further detail in this article.
Completed and Ongoing Trials
TrialDesign. A randomized, double-blind placebo-con-
trolled add-on design was recommended by the
MATRICS panel17 and is the primary design used in
CIAS trials (55.7% of all completed and 63.9% of all on-
going trials) (figure 2). Crossover or monotherapy trials
were less frequent, possibly due to the concern of the util-
ity of crossover study designs in cognition studies22 and
the lack of a clear regulatory path to obtaining approval















Test-retest Reliability (Intra-class Correla�on, ICC)
Sample Size Required Per Treatment Group
Fig. 1. Anillustrationof sample size requirements toachieve sufficientpower (beta5 .80)baseduponestimatedeffect size (cohen’sd) and test-
retest reliability (intraclass correlation [ICC]).
Fig. 2. Trial designs used in completed and ongoing trials.
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psychological assessments varied across the remainder of
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MATRICS panel17 and is the primary design used in
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Mechanisms of Action Studied. The studies included
many pharmacological treatments with diverse pharma-
cological mechanisms of action (MoA) (see online sup-
plementary tables 1–5). The following MoAs have
been or are currently being examined in 2 ormore studies:
NMDA receptor modulation, NMDA glycine site ago-
nism/partial agonism, NMDA glycine site antagonism,
H3 antagonism, selective activation of hypothalamic
regions associated with wakefulness noradrenergic recep-
tor reuptake inhibition, acetylcholine esterase inhibitors,
a7 receptors agonism/partial agonism, a4b2 nicotinic
receptors partial agonism, cannabinoid receptor antago-
nism, D2 partial agonismþ 5-HT2A antagonism, and D1/
D2 agonism. Agents acting at the NMDA receptor were
the most frequently examined class of agents.
Completed Trials. Among the 61 completed trials (fig-
ure 2), 34(55.7%) used double blind, randomized, pla-
cebo-controlled add-on design; 7(11.5%) used
randomized, double-blind, placebo-controlled crossover
design; 3(4.9%) used add-on open-label design; and
17(27.9%) were monotherapy trials. No clear preference
or consistency in the primary neurocognitive outcome
measure was observed. Results of 50.0% of add-on trials
and 22.0% of trials using other designs were available in
the public domain.
OngoingTrials. Among the 57 ongoing trials, 31(68.4%)
are add-on trials; 5(8.8%) are crossover trials, 7(12.3%)
are open label, and 6(10.5%) are monotherapy trials.
In 79.5% (N = 31) of the ongoing add-on trials and in
88.9% (N = 16) of ongoing trials using other designs, re-
cruitment began since 2007. TheMCCB18,19 (either alone
or in combination with another neurocognitive assess-
ment battery) is the primary outcome measure in
53.8% (N = 21) of ongoing add-on trials and in 38.9%
(N = 7) of ongoing trials using other designs.
Characteristics of Completed and Ongoing Add-on Trials
Sample Size. A similar distribution of sample sizes was
observed for both completed trials and ongoing trials
(figure 3). However, only 17.6% of completed and
35.9% of ongoing trials report a sample size that was
or is anticipated to be sufficient to produce statistical
power to detect a medium (d = 0.5) effect size, which
requires 71 subjects per group (using 2-arm trial with
drug and placebo) assuming the primary outcome mea-
sure has excellent test-retest reliability (ICC = .90) as with
the MCCB composite score21 (see online supplementary
tables 2 and 4).
Trial Duration. While the trial duration was �8 weeks
in the majority of completed trials (58.8%), there is a pat-
tern of longer duration among ongoing trials, with 66.7%
being >8 weeks long. Nevertheless, despite a moderate
shift toward longer trial duration, the length of 33.3%
of ongoing trials is �8 weeks.
Outcome Variables Used to Assess Cognitive Impairment.
Among the completed add-on trials, no clear prefer-
ence or consistency in the primary outcome measures
was observed (see online supplementary figure 1). No spe-
cific information about the primary outcome variable was
available for 29.4% of completed add-on trials, while the
MCCB18,19 (alone or in combination with other cognitive
testsbatteries,eg,BriefAssessmentofCognitioninSchizo-
phrenia [BACS23]) or Cambridge Neuropsychological
Fig. 3. Total sample size in completed and ongoing add-on trials.
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Test Automated Battery (CANTAB24) was used in 14.7%
of these trials (see online supplementary figure 1). Other
neuropsychologicalbatteries (eg,BACS23orCANTAB24)
were used in 20.6% trials and various cognitive domain-
specific tests in 35.3% of completed trials.
In 79.5% of the ongoing add-on trials, recruitment be-
gan since the development of the MCCB.18,19 In 53.8% of
ongoing add-on trials, the MCCB (alone or in combin-
ation with other neurocognitive test batteries such as
BACS,23 CANTAB,24 or CogState Schizophrenia Battery
—CSSB25) is the primary outcome measure (see online
supplementary figure 1). Use of other batteries or do-
main-specific test is limited in the ongoing add-on trials
(each in 12.8% of trials).
Functional Endpoints. No precise information on func-
tional outcomeor functional capacitymeasureswas avail-
able for themajorityof completed (25/73.5%)andongoing
(35/89.7%) trials. In those that reported a functional out-
come, theUniversityofCaliforniaSanDiegoPerformance
Skills Assessment26 was the most frequently used func-
tional capacity measure; it was included in 4/11.8% of
the completed and 4/10.3% of the ongoing trials. Other
measures included the Global Assessment of Function-
ing27 and the Strauss-Carpenter Level of Functioning
Scale.28
Participant Population Characteristics. Age Baseline
characteristics of subjects included in the completed stud-
ies with available results (N = 17) are summarized in table
1. In general, completed add-on studies recruited stable
subjects with schizophrenia between 18 and up to 60–
65 years of age. Mean age ranged between 25.1 and
52.7 across the treatment groups; in the majority of stud-
ies it was between 40 and 49 years. The only outlier with
respect to the age inclusion criterion was a trial of
minocycline, 29 which included subjects with recent onset
schizophrenia between 18 and 35 years. Among these 17
completed studies, the mean age of illness onset was
reported in only 2 studies (11%–8%; onset at 22.7–25.9
y of age across the treatment groups) and mean duration
of illness in 7 studies (41.2%; ranging between 13.0 and
25.5 y across the treatment groups). In general, ongoing
add-on trials are recruiting subjects typically 18 to 55/60/
65 years of age (see online supplementary table 4). The
exceptions are 5 trials (8.8%), 3 of which included subjects
35 years old, one between 18 and 45 years and one be-
tween 18 and 50 years.
Sex Participants of both sexes were recruited in the
completed studies; male subjects were in a clear majority,
with 68% men across all study samples. Ongoing add-on
trials are recruiting subjects of both sexes (see online sup-
plementary table 4).
Baseline Cognitive Impairment as Inclusion Criterion A
defined level of cognitive impairment was used as an
inclusion criterion in 20.6% of the completed and 15.4%
of the ongoing add-on trials (see online supplementary
tables 2 and 4). However, there was no consistency in
the choice of definitions of cognitive impairment used
across the studies.
BaselineCognitive ImpairmentofSubjects Included in the
Completed Trials Based on the available data (table 1),
the subjects included in the completed trials had at least
a minimal level of cognitive impairment. The MCCB18,19
was used in 2 trials with available results. In the armoda-
finil trial, 31mean baselineMCCB composite scores (SD)
ranged between 20.8(8.5) and 27.8(8.6) across the treat-
ment groups. In the MK-0777 trial, 37 the mean scores
ranged between 27.9 (12.2) and 31.0(12.6). These num-
bers are consistent with the MCCB screening scores of
323 patients in the 29-site lurasidone vs risperidone trial,
for which treatment results are not yet available.21 The
mean baseline score for the entire study sample in that
trial was 24.7 (12.1).21 In 6 ongoing trials (15.4%), inclu-
sion criteria defined an acceptable level of baseline cog-
nitive impairment (see online supplementary table 4).
Results of Completed Add-on Trials. The summary of
available trial results is presented in table 1.
Only one of the above studies with available results (see
table 1) had sufficient power to detect a medium (d = 0.5)
effect size, while several studies had sufficient power to
detect a large (d = 0.8) effect. None of the 346–48 com-
pleted crossover trials with available results reported
any significant effects of drug on cognitive performance
compared with the placebo (see online supplementary ta-
ble 3). Only 2 of 6 completed monotherapy trials are cur-
rently published49,50 but without results of
neurocognitive testing.
Discussion
Our search of www.clinicaltrials.gov identified 118 CIAS
trials that satisfied criteria for inclusion in our analysis. It
should be noted that, despite its size, www.clinicaltrials.-
gov is only one among many national and international
clinical trial registries, and therefore while the data
obtained on CIAS clinical trials are informative, they
are not exhaustive. In addition, some older trials may
not be registered at www.clinicaltrials.gov, or some trials
may not have been identified in the search and therefore
omitted from this analysis. Our analysis showed that add-
on, placebo-controlled, double-blind design is predomi-
nant across terminated, completed, and ongoing trials
and that the use of widely accepted standardized cogni-
tive batteries is increasing. However, other critical meth-
odological issues, such as sample sizes to achieve
standard statistical power, appear to be suboptimal in
many studies. The studies included pharmacological
treatments with many diverse mechanisms of action,
though agents acting at the NMDA receptor have
been examined most frequently. The lack of available
5
Potential Cognitive-Enhancing Drugs in Schizophrenia
421
Potential Cognitive-Enhancing Drugs in Schizophrenia
Mechanisms of Action Studied. The studies included
many pharmacological treatments with diverse pharma-
cological mechanisms of action (MoA) (see online sup-
plementary tables 1–5). The following MoAs have
been or are currently being examined in 2 ormore studies:
NMDA receptor modulation, NMDA glycine site ago-
nism/partial agonism, NMDA glycine site antagonism,
H3 antagonism, selective activation of hypothalamic
regions associated with wakefulness noradrenergic recep-
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35.9% of ongoing trials report a sample size that was
or is anticipated to be sufficient to produce statistical
power to detect a medium (d = 0.5) effect size, which
requires 71 subjects per group (using 2-arm trial with
drug and placebo) assuming the primary outcome mea-
sure has excellent test-retest reliability (ICC = .90) as with
the MCCB composite score21 (see online supplementary
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in the majority of completed trials (58.8%), there is a pat-
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Test Automated Battery (CANTAB24) was used in 14.7%
of these trials (see online supplementary figure 1). Other
neuropsychologicalbatteries (eg,BACS23orCANTAB24)
were used in 20.6% trials and various cognitive domain-
specific tests in 35.3% of completed trials.
In 79.5% of the ongoing add-on trials, recruitment be-
gan since the development of the MCCB.18,19 In 53.8% of
ongoing add-on trials, the MCCB (alone or in combin-
ation with other neurocognitive test batteries such as
BACS,23 CANTAB,24 or CogState Schizophrenia Battery
—CSSB25) is the primary outcome measure (see online
supplementary figure 1). Use of other batteries or do-
main-specific test is limited in the ongoing add-on trials
(each in 12.8% of trials).
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able for themajorityof completed (25/73.5%)andongoing
(35/89.7%) trials. In those that reported a functional out-
come, theUniversityofCaliforniaSanDiegoPerformance
Skills Assessment26 was the most frequently used func-
tional capacity measure; it was included in 4/11.8% of
the completed and 4/10.3% of the ongoing trials. Other
measures included the Global Assessment of Function-
ing27 and the Strauss-Carpenter Level of Functioning
Scale.28
Participant Population Characteristics. Age Baseline
characteristics of subjects included in the completed stud-
ies with available results (N = 17) are summarized in table
1. In general, completed add-on studies recruited stable
subjects with schizophrenia between 18 and up to 60–
65 years of age. Mean age ranged between 25.1 and
52.7 across the treatment groups; in the majority of stud-
ies it was between 40 and 49 years. The only outlier with
respect to the age inclusion criterion was a trial of
minocycline, 29 which included subjects with recent onset
schizophrenia between 18 and 35 years. Among these 17
completed studies, the mean age of illness onset was
reported in only 2 studies (11%–8%; onset at 22.7–25.9
y of age across the treatment groups) and mean duration
of illness in 7 studies (41.2%; ranging between 13.0 and
25.5 y across the treatment groups). In general, ongoing
add-on trials are recruiting subjects typically 18 to 55/60/
65 years of age (see online supplementary table 4). The
exceptions are 5 trials (8.8%), 3 of which included subjects
35 years old, one between 18 and 45 years and one be-
tween 18 and 50 years.
Sex Participants of both sexes were recruited in the
completed studies; male subjects were in a clear majority,
with 68% men across all study samples. Ongoing add-on
trials are recruiting subjects of both sexes (see online sup-
plementary table 4).
Baseline Cognitive Impairment as Inclusion Criterion A
defined level of cognitive impairment was used as an
inclusion criterion in 20.6% of the completed and 15.4%
of the ongoing add-on trials (see online supplementary
tables 2 and 4). However, there was no consistency in
the choice of definitions of cognitive impairment used
across the studies.
BaselineCognitive ImpairmentofSubjects Included in the
Completed Trials Based on the available data (table 1),
the subjects included in the completed trials had at least
a minimal level of cognitive impairment. The MCCB18,19
was used in 2 trials with available results. In the armoda-
finil trial, 31mean baselineMCCB composite scores (SD)
ranged between 20.8(8.5) and 27.8(8.6) across the treat-
ment groups. In the MK-0777 trial, 37 the mean scores
ranged between 27.9 (12.2) and 31.0(12.6). These num-
bers are consistent with the MCCB screening scores of
323 patients in the 29-site lurasidone vs risperidone trial,
for which treatment results are not yet available.21 The
mean baseline score for the entire study sample in that
trial was 24.7 (12.1).21 In 6 ongoing trials (15.4%), inclu-
sion criteria defined an acceptable level of baseline cog-
nitive impairment (see online supplementary table 4).
Results of Completed Add-on Trials. The summary of
available trial results is presented in table 1.
Only one of the above studies with available results (see
table 1) had sufficient power to detect a medium (d = 0.5)
effect size, while several studies had sufficient power to
detect a large (d = 0.8) effect. None of the 346–48 com-
pleted crossover trials with available results reported
any significant effects of drug on cognitive performance
compared with the placebo (see online supplementary ta-
ble 3). Only 2 of 6 completed monotherapy trials are cur-
rently published49,50 but without results of
neurocognitive testing.
Discussion
Our search of www.clinicaltrials.gov identified 118 CIAS
trials that satisfied criteria for inclusion in our analysis. It
should be noted that, despite its size, www.clinicaltrials.-
gov is only one among many national and international
clinical trial registries, and therefore while the data
obtained on CIAS clinical trials are informative, they
are not exhaustive. In addition, some older trials may
not be registered at www.clinicaltrials.gov, or some trials
may not have been identified in the search and therefore
omitted from this analysis. Our analysis showed that add-
on, placebo-controlled, double-blind design is predomi-
nant across terminated, completed, and ongoing trials
and that the use of widely accepted standardized cogni-
tive batteries is increasing. However, other critical meth-
odological issues, such as sample sizes to achieve
standard statistical power, appear to be suboptimal in
many studies. The studies included pharmacological
treatments with many diverse mechanisms of action,
though agents acting at the NMDA receptor have
been examined most frequently. The lack of available
5
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results for many trials precluded any assessment of the
most promising mechanisms of action.
What Has Been Learned So Far?
In general, a majority of completed and ongoing trials
follow the MATRICS guidelines17 for studying an ad-
junctive/cotreatment agent in a randomized, placebo-
controlled trial consisting of clinically stable participants
with schizophrenia.17,51–53
Compared with the ongoing trials, the completed add-
on trials were shorter, had smaller sample sizes, and were
less consistent in choice of cognitive outcome measures.
Since published results were available for only half of the
completed trials, the conclusions we can draw about the
overall success of these trials are limited. In general, the
completed trials, as well as the subset with available
results, were predominantly of 8 weeks duration. The
sole exception was a trial29 that assessed the effects of
a 6-month add-on treatment with either minocycline or
placebo on cognitive impairment in young subjects in
early phase schizophrenia, aged 18–35 years. In this
study, minocycline, a tetracycline antibiotic with a dis-
tinct neuroprotective profile, was found to be signifi-
cantly superior to placebo at endpoint in improving
cognitive functioning as well as negative symptoms
and general outcome.29 The original MATRICS guide-
lines17 specify that a phase 3 registration trial should
be of sufficient duration to show an enduring effect on
cognition (ie, at least 6 months), and this recommenda-
tion remained unchanged in their recent revision.20 The
majority of trials reviewed here appear to have been
proof-of-concept trials with a shorter duration. This ap-
proach is reasonable given the associated expense of lon-
ger studies that entail significant financial risk without
conferring sufficient guarantee of an efficacy signal. In
addition, there is insufficient data to support the propo-
sition that longer study duration is associated with better
results in neurocognition.
Typically, completed trials tended to have a sample size
of <100 subjects, with many enrolling <50 subjects. The
authors of several recently published add-on trials have
commented that their negative results could have been
related to limited sample sizes and the resulting low sta-
tistical power to detect changes in cognitive scores.38,43,44
Our analysis shows that only one in 17 completed trials
with available results had sufficient power to detect a me-
dium (d = 0.5) effect size, thus increasing the likelihood of
a type II statistical error of concluding that a drug with
true efficacy did not have beneficial effect.54,55 Some of
the studies included in this analysis were conducted in the
early phases of drug development and in keeping with
their exploratory nature, involved small sample sizes.
Given the large investment in time and resources required
to run larger trials, small-sample studies and those that
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pivotal trial, such as open-label studies, can contribute
valuable evidence of efficacy and safety. These early-
phase studies assist drug developers in making important
decisions about whether to invest financial resources in
a drug’s development. The application of nonstandard
thresholds for statistical significance is reasonable in
these circumstances, as is targeting patient populations
that may be the most responsive to treatment. However,
the results of underpowered studies such as those
reviewed here, especially when negative, should be inter-
preted with caution.56,57 The fact that the overwhelming
majority of studies reviewed here have not had sufficient
statistical power challenges the field to draw accurate
general conclusions about the potential for drug develop-
ment for CIAS.
Most of the studies reviewed recruited clinically stable
people with schizophrenia, aged between 18 and 55/60/65
years with a mean age between 40 and 49 years. Other
age-related variables, such as age at disease onset or years
since diagnosis, which may serve as a proxy for schizo-
phrenia chronicity, were rarely reported. Although cog-
nitive impairments are generally stable over relatively
short periods of time in the longitudinal course of schizo-
phrenia58–60 cognitive function is age dependent in
healthy controls and schizophrenia samples. Larger def-
icits in working memory have been shown to exist in el-
derly vs first-episode people with schizophrenia, while
worse recall of material in episodic memory, changes
in select time-based measures of problem solving and
fine motor dexterity have all been associated with greater
length of illness.61,62 In some studies of behavioral inter-
ventions not reviewed comprehensively in this report,
younger people with schizophrenia and those early in
the course of illness appeared to benefit more from cog-
nitive remediation than older people.63–65 Although the
sample of chronic, stable participants with schizophrenia
may be relatively convenient to recruit, these may not be
the individuals who are most likely to show improve-
ments in cognition.66 A trial performed in younger sub-
jects with recent illness onset29 may yield more positive
results than those conducted in patients with an average
illness duration of>20 years (See table 1). It is reasonable
to expect that younger patients with greater potential
neuroplasticity may be optimal candidates for pharmaco-
logical intervention, but surprisingly, few data are avail-
able that address this question empirically.
What Are We Likely to Learn From Ongoing Studies?
Compared with the completed-add-on trials, the ongoing
add-on trials are longer, have larger sample sizes, and are
more likely to use a widely accepted standardized cogni-
tive battery (eg, MCCB18,19). This suggests that the
MATRICS recommendations are being implemented
in the more recent trials. The ongoing trials generally al-
low for recruitment of subjects aged between 18 and 55–
65 years, and it is likely that the actual age range will be
comparable to the completed studies. However, 3 ongo-
ing add-on studies are recruiting recent onset subjects;
their results may help to determine which subjects are
most likely to experience cognitive benefits.66 The level
of baseline cognitive impairment was defined in few on-
going trials. The MATRICS guidelines17 noted that in
general, it is not necessary to exclude subjects with
a high level of cognitive functioning in whom further im-
provement in cognition would not be expected to be dem-
onstrated because with a properly constructed cognitive
test battery, this level of performance is very rare. How-
ever, the question remains whether severely cognitively
impaired subjects should be enrolled into CIAS trials.
We still do not know the extent to which the presence
of a ‘‘floor’’ effect on a cognitive test indicates minimal
capacity for cognitive improvement. Analysis of extant
cognitive data from previously completed studies could
address whether severely impaired patients are negating
an overall clinical benefit of a treatment, and surpris-
ingly, little work in this area has been completed.
Among the ongoing add-on trials, 30.7% estimated an
expected enrollment of100 subjects. Such large samples
imply multi-site trials, which present investigators and
sponsors with specific challenges (for review, see
ref.54). For international clinical trials, it is also impor-
tant to ensure the cross-cultural and linguistic adaptabil-
ity of primary67 and coprimary outcome measures.68
Several large-scale multisite studies, including interna-
tional trials, are currently underway, and upon their com-
pletion, it may be possible to determine whether specific
recommendations for performing multisite trials with
neurocognitive assessments have been successfully imple-
mented, and how these recommendations may impact tri-
al results. Early results suggest that good psychometric
characteristics of the cognitive outcome measure are pos-
sible in large multisite studies if sufficient care is given to
training and data quality.21 Our results also show that the
percentage of ongoing add-on trials with sufficient statis-
tical power to detect medium effect sizes has doubled in
comparison to the completed add-on trials. However,
more than half of ongoing trials still may have inadequate
sample sizes. Although adequate sample size is an impor-
tant determinant in the estimation of statistical power in
each study, an important and underappreciated compo-
nent of statistical power calculations is that relatively
small changes in the reliability of the neurocognitive end-
points can have a strong effect on the sample size needed,
especially when the magnitude of the expected effect is
small to medium. It has been demonstrated that the
MCCB18,19 has excellent reliability, minimal practice
effects, and significant correlations with measures of
functional capacity. These favorable psychometric prop-
erties have also been observed in the context of a large
multisite industry trial for which it was designed.21 How-
ever, it is still not confirmed whether the MCCB is
15
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results for many trials precluded any assessment of the
most promising mechanisms of action.
What Has Been Learned So Far?
In general, a majority of completed and ongoing trials
follow the MATRICS guidelines17 for studying an ad-
junctive/cotreatment agent in a randomized, placebo-
controlled trial consisting of clinically stable participants
with schizophrenia.17,51–53
Compared with the ongoing trials, the completed add-
on trials were shorter, had smaller sample sizes, and were
less consistent in choice of cognitive outcome measures.
Since published results were available for only half of the
completed trials, the conclusions we can draw about the
overall success of these trials are limited. In general, the
completed trials, as well as the subset with available
results, were predominantly of 8 weeks duration. The
sole exception was a trial29 that assessed the effects of
a 6-month add-on treatment with either minocycline or
placebo on cognitive impairment in young subjects in
early phase schizophrenia, aged 18–35 years. In this
study, minocycline, a tetracycline antibiotic with a dis-
tinct neuroprotective profile, was found to be signifi-
cantly superior to placebo at endpoint in improving
cognitive functioning as well as negative symptoms
and general outcome.29 The original MATRICS guide-
lines17 specify that a phase 3 registration trial should
be of sufficient duration to show an enduring effect on
cognition (ie, at least 6 months), and this recommenda-
tion remained unchanged in their recent revision.20 The
majority of trials reviewed here appear to have been
proof-of-concept trials with a shorter duration. This ap-
proach is reasonable given the associated expense of lon-
ger studies that entail significant financial risk without
conferring sufficient guarantee of an efficacy signal. In
addition, there is insufficient data to support the propo-
sition that longer study duration is associated with better
results in neurocognition.
Typically, completed trials tended to have a sample size
of <100 subjects, with many enrolling <50 subjects. The
authors of several recently published add-on trials have
commented that their negative results could have been
related to limited sample sizes and the resulting low sta-
tistical power to detect changes in cognitive scores.38,43,44
Our analysis shows that only one in 17 completed trials
with available results had sufficient power to detect a me-
dium (d = 0.5) effect size, thus increasing the likelihood of
a type II statistical error of concluding that a drug with
true efficacy did not have beneficial effect.54,55 Some of
the studies included in this analysis were conducted in the
early phases of drug development and in keeping with
their exploratory nature, involved small sample sizes.
Given the large investment in time and resources required
to run larger trials, small-sample studies and those that
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pivotal trial, such as open-label studies, can contribute
valuable evidence of efficacy and safety. These early-
phase studies assist drug developers in making important
decisions about whether to invest financial resources in
a drug’s development. The application of nonstandard
thresholds for statistical significance is reasonable in
these circumstances, as is targeting patient populations
that may be the most responsive to treatment. However,
the results of underpowered studies such as those
reviewed here, especially when negative, should be inter-
preted with caution.56,57 The fact that the overwhelming
majority of studies reviewed here have not had sufficient
statistical power challenges the field to draw accurate
general conclusions about the potential for drug develop-
ment for CIAS.
Most of the studies reviewed recruited clinically stable
people with schizophrenia, aged between 18 and 55/60/65
years with a mean age between 40 and 49 years. Other
age-related variables, such as age at disease onset or years
since diagnosis, which may serve as a proxy for schizo-
phrenia chronicity, were rarely reported. Although cog-
nitive impairments are generally stable over relatively
short periods of time in the longitudinal course of schizo-
phrenia58–60 cognitive function is age dependent in
healthy controls and schizophrenia samples. Larger def-
icits in working memory have been shown to exist in el-
derly vs first-episode people with schizophrenia, while
worse recall of material in episodic memory, changes
in select time-based measures of problem solving and
fine motor dexterity have all been associated with greater
length of illness.61,62 In some studies of behavioral inter-
ventions not reviewed comprehensively in this report,
younger people with schizophrenia and those early in
the course of illness appeared to benefit more from cog-
nitive remediation than older people.63–65 Although the
sample of chronic, stable participants with schizophrenia
may be relatively convenient to recruit, these may not be
the individuals who are most likely to show improve-
ments in cognition.66 A trial performed in younger sub-
jects with recent illness onset29 may yield more positive
results than those conducted in patients with an average
illness duration of>20 years (See table 1). It is reasonable
to expect that younger patients with greater potential
neuroplasticity may be optimal candidates for pharmaco-
logical intervention, but surprisingly, few data are avail-
able that address this question empirically.
What Are We Likely to Learn From Ongoing Studies?
Compared with the completed-add-on trials, the ongoing
add-on trials are longer, have larger sample sizes, and are
more likely to use a widely accepted standardized cogni-
tive battery (eg, MCCB18,19). This suggests that the
MATRICS recommendations are being implemented
in the more recent trials. The ongoing trials generally al-
low for recruitment of subjects aged between 18 and 55–
65 years, and it is likely that the actual age range will be
comparable to the completed studies. However, 3 ongo-
ing add-on studies are recruiting recent onset subjects;
their results may help to determine which subjects are
most likely to experience cognitive benefits.66 The level
of baseline cognitive impairment was defined in few on-
going trials. The MATRICS guidelines17 noted that in
general, it is not necessary to exclude subjects with
a high level of cognitive functioning in whom further im-
provement in cognition would not be expected to be dem-
onstrated because with a properly constructed cognitive
test battery, this level of performance is very rare. How-
ever, the question remains whether severely cognitively
impaired subjects should be enrolled into CIAS trials.
We still do not know the extent to which the presence
of a ‘‘floor’’ effect on a cognitive test indicates minimal
capacity for cognitive improvement. Analysis of extant
cognitive data from previously completed studies could
address whether severely impaired patients are negating
an overall clinical benefit of a treatment, and surpris-
ingly, little work in this area has been completed.
Among the ongoing add-on trials, 30.7% estimated an
expected enrollment of100 subjects. Such large samples
imply multi-site trials, which present investigators and
sponsors with specific challenges (for review, see
ref.54). For international clinical trials, it is also impor-
tant to ensure the cross-cultural and linguistic adaptabil-
ity of primary67 and coprimary outcome measures.68
Several large-scale multisite studies, including interna-
tional trials, are currently underway, and upon their com-
pletion, it may be possible to determine whether specific
recommendations for performing multisite trials with
neurocognitive assessments have been successfully imple-
mented, and how these recommendations may impact tri-
al results. Early results suggest that good psychometric
characteristics of the cognitive outcome measure are pos-
sible in large multisite studies if sufficient care is given to
training and data quality.21 Our results also show that the
percentage of ongoing add-on trials with sufficient statis-
tical power to detect medium effect sizes has doubled in
comparison to the completed add-on trials. However,
more than half of ongoing trials still may have inadequate
sample sizes. Although adequate sample size is an impor-
tant determinant in the estimation of statistical power in
each study, an important and underappreciated compo-
nent of statistical power calculations is that relatively
small changes in the reliability of the neurocognitive end-
points can have a strong effect on the sample size needed,
especially when the magnitude of the expected effect is
small to medium. It has been demonstrated that the
MCCB18,19 has excellent reliability, minimal practice
effects, and significant correlations with measures of
functional capacity. These favorable psychometric prop-
erties have also been observed in the context of a large
multisite industry trial for which it was designed.21 How-
ever, it is still not confirmed whether the MCCB is
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sensitive to change during pharmacological treatment. As
its use has substantially increased in ongoing add-on tri-
als, a wealth of data regarding this issue will be available
in the next few years. To accommodate the needs of mul-
tinational trials, the MCCB has been translated into
a range of languages.67 Recently, the reliability, validity,
and practicality of functionally meaningful co-primary
measures was established,68 and the MCCB impairment
profile for schizophrenia outpatients became available.69
Our search revealed the use of neuropsychological test
batteries other than the MCCB (eg, BACS,23 CAN-
TAB,24 and CSSB25), though their use is somewhat lim-
ited in the ongoing trials. Future results may contribute
to our understanding of their psychometric characteris-
tics within the context of large multisite trials.
No clear pattern could be established in the choice of
co-primary outcome related to functioning or functional
capacity in either completed or ongoing trials. While the
MATRICS initiative made clear recommendations re-
garding the cognitive outcome measure, it did not
make strong recommendations about the choice of func-
tional capacity measures, and several different strategies
were considered to be acceptable. The recent VIM study68
suggests that there are no optimal co-primary measures,
although several of them have reasonable psychometric
characteristics. The performance of these measures in
currently ongoing trials will provide additional practical
information about their utility for future work.
Possible Reasons and Contributing Factors Related to
Negative Study Results
Since half of the completed trials do not have results in
the public domain and even fewer in the peer-reviewed
literature, it is unfortunately challenging to make any re-
liable appraisals of the factors that may be associated
with negative trial results. The possible methodological
reasons for the lack of effect of co-treatment with poten-
tially cognitive-enhancing drugs are varied. The main
conclusion from our review of these studies is that
most of the studies had woefully inadequate statistical
power. Ongoing studies appear to have greater statistical
power and the opportunity for positive results is greater.
While crossover designs for cognitive outcomes are ap-
pealing due to their capacity to enhance power through
within-subjects analyses, these trials may obscure effects
that could be seen in parallel group studies because prac-
tice effects and treatment effects may be confounded.22
Although the possibility of genetic mediation of improve-
ments in neurocognitive deficits is intriguing, the initial
findings to date will require replication and functional
validation.70
How May These Lessons Help Shape Future Trials?
Based on the information gathered in our analysis, we
summarized the key issues pertinent to the implementa-
tion and conduct of trials assessing potential cognitive-
enhancing drugs in schizophrenia and possible solutions
(table 2).
Conclusions
A review of the trials listed on www.clinicaltrials.gov sug-
gests that a substantial number of clinical trials of poten-
tial treatments for cognitive enhancement in
schizophrenia are currently ongoing. The studies com-
pleted to date have not had sufficient statistical power
to state confidently that a particular treatment does
not have potential efficacy. Further, the predominant pa-
tient population in these studies has been older, chronic,
andmostlymale patients with schizophrenia, whomay be
the least likely to benefit from cognitive enhancement.
Many ongoing studies have larger and more diverse sam-
ples and are likely to shed a brighter light on the chal-
lenges of CIAS trial design and methodology. These
ongoing efforts may increase the probability of identify-
ing treatments with beneficial effect on cognitive impair-
ment in schizophrenia.
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tional capacity measures, and several different strategies
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suggests that there are no optimal co-primary measures,
although several of them have reasonable psychometric
characteristics. The performance of these measures in
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with negative trial results. The possible methodological
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within-subjects analyses, these trials may obscure effects
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tice effects and treatment effects may be confounded.22
Although the possibility of genetic mediation of improve-
ments in neurocognitive deficits is intriguing, the initial
findings to date will require replication and functional
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Based on the information gathered in our analysis, we
summarized the key issues pertinent to the implementa-
tion and conduct of trials assessing potential cognitive-
enhancing drugs in schizophrenia and possible solutions
(table 2).
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gests that a substantial number of clinical trials of poten-
tial treatments for cognitive enhancement in
schizophrenia are currently ongoing. The studies com-
pleted to date have not had sufficient statistical power
to state confidently that a particular treatment does
not have potential efficacy. Further, the predominant pa-
tient population in these studies has been older, chronic,
andmostlymale patients with schizophrenia, whomay be
the least likely to benefit from cognitive enhancement.
Many ongoing studies have larger and more diverse sam-
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